• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [23806 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2027     Norwegian Medical Products Agency (NOMA) [Wearable cardioverter defibrillator (LifeVest) for people with high risk of sudden cardiac arrest: a single technology assessment]
2027     Belgian Health Care Knowledge Centre (KCE) Review of new oncology indications for the use of positron emission tomography (PET-scans) (Study 2024-12)
2026     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Barriers and facilitators when implementing guidelines in health and social care for the elderly]
2026     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of Nirmatrelvir plus ritonavir (Paxlovid)]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Review of the lower age limit and frequency of early-detection colonoscopy in the colorectal cancer screening programme]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Acupuncture for migraine prophylaxis]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Newborn screening for metachromatic leukodystrophy]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [X-ray image of the lung: Can artificial intelligence support the analysis of X-ray images?]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Quality of sleep: Can taking melatonin as a dietary supplement, e.g. in the form of tablets, sprays or soft gums, help to improve sleep?]
2026     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Reinforced foster homes]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Tumor biomarkers related to the management of bladder cancer patients]
2025     NIHR Health and Social Care Delivery Program Optimising neonatal services for very preterm births between 27+0 and 31+6 weeks gestation in England: the OPTI-PREM mixed-methods study
2025     NIHR Health and Social Care Delivery Program Organising general practice for care homes: a multi-method study
2025     HTA South [Ultraviolet light disinfection of flexible endoscopes without working channels: a systematic review and assessment of medical, economical, and organisational aspects]
2025     NIHR Health and Social Care Delivery Program Exploring voluntary sector specialist services for victim-survivors of sexual violence in England: the PROSPER co-production study
2025     NIHR Health and Social Care Delivery Program Direct oral penicillin challenge in secondary care with low-risk patients: the SPACE mixed-methods study with cost-effectiveness analysis
2025     NIHR Health Technology Assessment programme Evaluation of prognostic models to improve prediction of metastasis in patients following potentially curative treatment for primary colorectal cancer: the PROSPECT trial
2025     NIHR Health Technology Assessment programme Supporting self-management with an internet intervention for low back pain in primary care: a RCT (SupportBack 2)
2025     NIHR Health and Social Care Delivery Program Formulating outputs from a mixed-methods study of access to general practice: a series of collaborative stakeholder workshops
2025     NIHR Health Technology Assessment programme Lessons from the PROTECT-CH COVID-19 platform trial in care homes
2025     NIHR Health Technology Assessment programme Stopping anticoagulation for isolated or incidental subsegmental pulmonary embolism: the challenges and lessons from the STOPAPE RCT
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Fibrin sealants and hemostatic matrices in an intraoperative context]
2025     NIHR Health Technology Assessment programme Anti-VEGF drugs compared with laser photocoagulation for the treatment of proliferative diabetic retinopathy: a systematic review and individual participant data meta-analysis
2025     NIHR Health Technology Assessment programme A personalised health intervention to maintain independence in older people with mild frailty: a process evaluation within the HomeHealth RCT
2025     NIHR Health Services and Delivery Research programme Multiple Symptoms Study 3 – an extended-role general practitioner clinic for patients with persistent physical symptoms: a randomised controlled trial
2025     NIHR Health Services and Delivery Research programme The impact of redeployment during COVID-19 on nurse well-being, performance and retention: a mixed-methods study (REDEPLOY)
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Arthrofibrosis (excessive scarring) in the knee: can surgical procedures reduce movement restrictions and pain?]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Hip osteoarthritis: can physiotherapy delay or avoid surgery?]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Capivasertib (breast cancer) – 2nd addendum to Project A24-105]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bulevirtide (chronic hepatitis D, children >= 3 to < 18 years, >= 10 kg) – assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eliglustat (Gaucher disease type 1; children and adolescents) – assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mirvetuximab soravtansin (ovarian cancer) – assessment in accordance with §35a (1) Sentence 11 Social Code Book (SGB) V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Delgocitinib (moderate to severe chronic hand eczema) – addendum to Project A24-107]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Capivasertib (breast cancer) – addendum to Project A24-105]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC, first line) – addendum to Project A24-97]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (urothelial cancer, first line treatment, combination with enfortumab vedotin) – addendum to Project A24-99]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enfortumab vedotin (urothelial cancer, first line treatment, combination with pembrolizumab) – addendum to Project A24-98]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sotatercept (pulmonary arterial hypertension) – addendum to Project A24-96]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Crovalimab (paroxysmal nocturnal haemoglobinuria) – addendum to Project A24-94]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Insulin icodec (type 1 diabetes mellitus) – addendum to Project A24-90]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Erdafitinib (urothelial carcinoma) – benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tislelizumab (gastric or gastroesophageal junction adenocarcinoma, HER2-negative) – benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tislelizumab (oesophageal squamous cell carcinoma, second line) – benefit assessment according to § 35a Social Code Book (SGB) V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tislelizumab (NSCLC, second line) - benefit assessment according to § 35a Social Code Book (SGB) V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tislelizumab (non-squamous NSCLC) - benefit assessment according to §35a Social Code Book (SGB) V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tislelizumab (squamous NSCLC, first line) – benefit assessment according to §35a Social Code Book (SGB) V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ribociclib (breast cancer, adjuvant treatment) – benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Linzagolix (endometriosis) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Osimertinib (NSCLC, combination with pemetrexed and platinum-based chemotherapy) – Addendum to Project A24-77]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (COPD) - addendum to project A24-79]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (eosinophilic oesophagitis, 1 to 11 years) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ciltacabtagene autoleucel (multiple myeloma, at least one prior therapy) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (newly diagnosed multiple myeloma, suitable for autologous stem cell transplant) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Benralizumab (eosinophilic granulomatosis with polyangiitis) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Apremilast (plaque psoriasis) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (endometrial carcinoma) – benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (cervical cancer, combination with chemoradiotherapy) – benefit assessment according to §35a Social Code Book V]
2025     Health Information and Quality Authority (HIQA) National guidelines for the budget impact analysis of health technologies in Ireland
2025     Health Information and Quality Authority (HIQA) National guidelines for the economic evaluation of health technologies in Ireland
2025     Health Information and Quality Authority (HIQA) Protocol: development of a tool for the collection of costs attributable to infectious disease outbreaks in public acute hospitals
2025     Health Information and Quality Authority (HIQA) The management of obesity in adults: protocol for a review of international clinical guidelines
2025     Health Information and Quality Authority (HIQA) The management of acute asthma attack in adults: protocol for a review of international clinical guidelines
2025     Health Information and Quality Authority (HIQA) Protocol for a health technology assessment of immunisation against respiratory syncytial virus in Ireland
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Blood testing for cystatin C by immunoturbidimetry]
2025     National Institute for Health and Care Excellence (NICE) Alcohol-mediated perivascular renal sympathetic denervation for resistant hypertension. NICE interventional procedures guidance 801
2025     National Institute for Health and Care Excellence (NICE) 12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites. NICE technology appraisal guidance 1045
2025     National Institute for Health and Care Excellence (NICE) Atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable (terminated appraisal). NICE technology appraisal guidance 1047
2025     National Institute for Health and Care Excellence (NICE) Zolbetuximab with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma. NICE technology appraisal guidance 1046
2025     National Institute for Health and Care Excellence (NICE) Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over. NICE technology appraisal guidance 1050
2025     National Institute for Health and Care Excellence (NICE) Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia. NICE technology appraisal guidance 1049
2025     National Institute for Health and Care Excellence (NICE) Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitable. NICE technology appraisal guidance 1048
2025     NIHR Health Technology Assessment programme A group psychological intervention for postnatal depression in British mothers of South Asian origin – the ROSHNI-2 RCT
2025     NIHR Health Technology Assessment programme Recent research in myalgic encephalomyelitis/chronic fatigue syndrome: an evidence map
2025     NIHR Health Technology Assessment programme Experiences of support to return to work after stroke: longitudinal case studies from RETAKE trial
2025     NIHR Health Technology Assessment programme Gait Rehabilitation for Early rheumatoid Arthritis Trial (GREAT): lessons learnt from a mixed-methods feasibility study and internal pilot trial
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Buccal cell sampling as a source of genetic material]
2025     Austrian Institute for Health Technology Assessment (AIHTA) [Reimbursement models and pricing of digital health technologies and telemonitoring applications – Rapid scoping review]
2025     Austrian Institute for Health Technology Assessment (AIHTA) Exagamglogene autotemcel (Exa-cel, Casgevy®)
2025     NIHR Health Technology Assessment programme Benefits of aldosterone receptor antagonism in chronic kidney disease: the BARACK-D RCT
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Appropriate use of cardiac monitoring in the emergency department]
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Prediction models in dental care - basis for the National Board of Health and Welfare’s mission to develop a national model for risk assessment in dental care]
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [ADHD and driving performance]
2025     Health Sciences Institute in Aragon (IACS) Programme for the use of real world data in health technology assessment: using real-world data for health technology assessment
2025     Penn Medicine Center for Evidence-based Practice (CEP) Dedicated staff for placement of indwelling urinary catheters
2025     NIHR Health Technology Assessment programme The acceptability of blood spot screening and genome sequencing in newborn screening: a systematic review examining evidence and frameworks
2025     NIHR Health Technology Assessment programme Management of diarrhoea in patients with stable ulcerative colitis with low FODMAP diet, amitriptyline, ondansetron or loperamide: the MODULATE RCT
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Bispecific and tumor-infiltrating T cell therapies: considerations for deployment in Quebec]
2025     Gesundheit Osterreich GmbH (GOeG) [Efficacy and safety of antibody therapies in early-stage Alzheimer's disease]
2025     NIHR Health Services and Delivery Research programme The implementation of safety management systems in healthcare: a systematic review and international comparison
2025     Scottish Health Technologies Group (SHTG) Stability of prostate specific antigen (PSA) in blood samples
2025     Scottish Health Technologies Group (SHTG) Artificial intelligence (AI) assisted endoscopy
2025     Scottish Health Technologies Group (SHTG) Vacuum bell device for people with pectus excavatum
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Effectiveness and safety of scalp cooling to prevent chemotherapy-induced alopecia (CIA)]
2025     National Institute for Health and Care Excellence (NICE) Intravascular lithotripsy to treat calcified coronary arteries during percutaneous coronary intervention. NICE interventional procedures guidance 802
2025     National Institute for Health and Care Excellence (NICE) Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment. NICE technology appraisal guidance 1036
2025     National Institute for Health and Care Excellence (NICE) Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer. NICE technology appraisal guidance 1037
2025     National Institute for Health and Care Excellence (NICE) Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy. NICE technology appraisal guidance 1040
2025     National Institute for Health and Care Excellence (NICE) Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over. NICE technology appraisal guidance 1039
2025     National Institute for Health and Care Excellence (NICE) Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over. NICE technology appraisal guidance 1038
2025     National Institute for Health and Care Excellence (NICE) Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over. NICE technology appraisal guidance 1033